AstraZeneca (AZN) Tops Q1 EPS by 20c

AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $1.92, $0.20 better than the analyst estimate of $1.72. Revenue for the quarter came in at $10.88 billion versus the consensus estimate of $10.69 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
• HSBC starts SpaceX at Hold, sees execution risks tempering long-term AI ambitions
• American Express (AXP) Tops Q2 EPS by 13c